These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33106136)

  • 1. DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis.
    Xu W; Wang B; Cai Y; Guo C; Liu K; Yuan C
    Curr Pharm Des; 2021; 27(20):2337-2343. PubMed ID: 33106136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis.
    Lu T; Wang R; Cai H; Cui Y
    Biomed Pharmacother; 2020 Mar; 123():109650. PubMed ID: 31884338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deleted in lymphocytic leukemia 2 (DLEU2): a possible biomarker that holds promise for future diagnosis and treatment of cancer.
    Qu X; Cao YX; Xing YX; Liu Q; Li HJ; Yang WH; Wang BQ; Han SY; Wang YS
    Clin Transl Oncol; 2023 Oct; 25(10):2772-2782. PubMed ID: 37095423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis.
    Zhou Y; Shi H; Du Y; Zhao G; Wang X; Li Q; Liu J; Ye L; Shen Z; Guo Y; Huang Y
    Aging (Albany NY); 2019 Sep; 11(18):7386-7401. PubMed ID: 31541993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway.
    Xie ZZ; Xiao ZC; Song YX; Li W; Tan GL
    Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1963-1970. PubMed ID: 29687850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p.
    Wu W; Zhao Y; Gao E; Li Y; Guo X; Zhao T; He W; Zhang H
    J Cell Mol Med; 2020 Jan; 24(1):441-450. PubMed ID: 31721438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA DLEU2 predicts a poor prognosis and enhances malignant properties in laryngeal squamous cell carcinoma through the miR-30c-5p/PIK3CD/Akt axis.
    Li X; Xu F; Meng Q; Gong N; Teng Z; Xu R; Zhao M; Xia M
    Cell Death Dis; 2020 Jun; 11(6):472. PubMed ID: 32555190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA DLEU2 promotes cervical cancer cell proliferation by regulating cell cycle and NOTCH pathway.
    He M; Wang Y; Cai J; Xie Y; Tao C; Jiang Y; Li H; Song F
    Exp Cell Res; 2021 May; 402(1):112551. PubMed ID: 33675808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors.
    Ji D; Zhong X; Jiang X; Leng K; Xu Y; Li Z; Huang L; Li J; Cui Y
    Pathol Res Pract; 2018 Oct; 214(10):1524-1531. PubMed ID: 30173945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deleted in lymphocytic leukemia 2 (DLEU2): An lncRNA with dissimilar roles in different cancers.
    Ghafouri-Fard S; Dashti S; Farsi M; Taheri M
    Biomed Pharmacother; 2021 Jan; 133():111093. PubMed ID: 33378985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DLEU1: A Functional Long Noncoding RNA in Tumorigenesis.
    Song C; Zhang J; Zhao Z; Yang Y; Meng D; Wang J; Guo C; Yuan C
    Curr Pharm Des; 2020; 26(15):1742-1748. PubMed ID: 31969095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA DLEU2 is activated by STAT1 and induces gastric cancer development via targeting miR-23b-3p/NOTCH2 axis and Notch signaling pathway.
    Li G; Zhang Z; Chen Z; Liu B; Wu H
    Life Sci; 2021 Jul; 277():119419. PubMed ID: 33785336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deleted in lymphocytic leukemia 2 induces retinoic acid receptor beta promoter methylation and mitogen activated kinase-like protein activation to enhance viability and mobility of colorectal cancer cells.
    Fu L; Shi Z; Chen B
    Bioengineered; 2022 May; 13(5):12847-12862. PubMed ID: 35611845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lncRNA-DLEU2/miR-186-5p/PDK3 axis promotes the progress of glioma cells.
    Xie Z; Li X; Chen H; Zeng A; Shi Y; Tang Y
    Am J Transl Res; 2019; 11(8):4922-4934. PubMed ID: 31497209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA DLEU2 promotes tumour growth by sponging miR-337-3p in human osteosarcoma.
    Liu W; Liu PC; Ma K; Wang YY; Chi QB; Yan M
    Cell Biochem Funct; 2020 Oct; 38(7):886-894. PubMed ID: 32196715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1.
    Li P; Xu H; Yang L; Zhan M; Shi Y; Zhang C; Gao D; Gu M; Chen Y; Wang Z
    Cell Death Dis; 2022 Jan; 13(1):77. PubMed ID: 35075115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2.
    Guo Y; Bai M; Lin L; Huang J; An Y; Liang L; Liu Y; Huang W
    Biomed Pharmacother; 2019 Oct; 118():109272. PubMed ID: 31376657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.
    Garding A; Bhattacharya N; Claus R; Ruppel M; Tschuch C; Filarsky K; Idler I; Zucknick M; Caudron-Herger M; Oakes C; Fleig V; Keklikoglou I; Allegra D; Serra L; Thakurela S; Tiwari V; Weichenhan D; Benner A; Radlwimmer B; Zentgraf H; Wiemann S; Rippe K; Plass C; Döhner H; Lichter P; Stilgenbauer S; Mertens D
    PLoS Genet; 2013 Apr; 9(4):e1003373. PubMed ID: 23593011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA-455.
    Xu B; Gong X; Zi L; Li G; Dong S; Chen X; Li Y
    Cancer Sci; 2019 May; 110(5):1676-1685. PubMed ID: 30838724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer.
    Xu W; Wang B; Cai Y; Chen J; Meng E; Guo C; Zhou G; Yuan C
    Curr Pharm Des; 2021; 27(39):4100-4106. PubMed ID: 34414867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.